Home Featured Page 112

Featured

Latest

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic Educators Network

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of...

Webinar – Integrative Harm Reduction Psychotherapy (IHRP) Rationale, Theory and Technique

PT391 – MDMA-Assisted Psychotherapy For Fibromyalgia and Other Central Sensitization Syndromes

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints...

Psychedelic Policy & Law in 2022

Psychedelics Take a Step Towards the Policy Agenda in Czechia

The Medical Potential of Psychedelics: A View from the European Union

AIMS v. DEA: Advocating for Open Access to Psilocybin Assisted Therapy

1...111112113...306 Page 112 of 306

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic Educators Network

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of...

Webinar – Integrative Harm Reduction Psychotherapy (IHRP) Rationale, Theory and Technique

PT391 – MDMA-Assisted Psychotherapy For Fibromyalgia and Other Central Sensitization Syndromes

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints...

Psychedelic Policy & Law in 2022

Psychedelics Take a Step Towards the Policy Agenda in Czechia

The Medical Potential of Psychedelics: A View from the European Union

AIMS v. DEA: Advocating for Open Access to Psilocybin Assisted Therapy

EDITOR PICKS

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

The Psychedelic News Feed: January 12 – 18, 2026

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY